DRUG DELIVERY DEVICES AND METHODS
First Claim
Patent Images
1. A method of treating an ocular disorder of an eye, comprising:
- forming a self-sealing incision in the cornea of the eye into the anterior chamber;
introducing through the incision an implant comprising a proximal end, a distal end, and an interior volume in fluid communication with at least one opening, wherein the interior volume is plugged with a drug-release material comprising at least one active agent;
passing the distal end and the proximal end of the implant through the anterior chamber;
positioning the distal end of the implant into the suprachoroidal space; and
eluting the at least one active agent from the drug-release material through the at least one opening to treat the eye, wherein the drug-release material degrades from the interior volume of the implant over a period of at least 12 hours.
3 Assignments
0 Petitions
Accused Products
Abstract
This disclosure relates generally to methods and devices for use in treating eye conditions with implantable drug delivery devices. One method includes introducing an implant into the suprachoroidal space, wherein the interior volume of the implant is plugged with a drug-release material comprising at least one active agent that elutes through at least one opening in the implant, wherein the drug-release material degrades from the interior volume of the implant over a period time.
-
Citations
36 Claims
-
1. A method of treating an ocular disorder of an eye, comprising:
-
forming a self-sealing incision in the cornea of the eye into the anterior chamber; introducing through the incision an implant comprising a proximal end, a distal end, and an interior volume in fluid communication with at least one opening, wherein the interior volume is plugged with a drug-release material comprising at least one active agent; passing the distal end and the proximal end of the implant through the anterior chamber; positioning the distal end of the implant into the suprachoroidal space; and eluting the at least one active agent from the drug-release material through the at least one opening to treat the eye, wherein the drug-release material degrades from the interior volume of the implant over a period of at least 12 hours. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method of treating an ocular disorder of an eye, comprising:
-
forming a self-sealing incision in the cornea into the anterior chamber of the eye; introducing through the incision an implant comprising a proximal end with at least one inflow port, a distal end with at least one outflow port, and an interior volume extending through the implant between the at least one inflow port and at least one outflow port, wherein the implant is mounted on a delivery wire of an implantation instrument extending through the interior volume of the implant; passing the distal end and the proximal end of the implant through the anterior chamber; positioning the distal end of the implant into the suprachoroidal space using the implantation instrument; and flowing a drug-release material comprising at least one active agent through the delivery wire of the implantation instrument and the interior volume of the implant. - View Dependent Claims (10, 11, 12, 13, 14, 15)
-
-
16. A method of delivering to the eye a therapeutic agent to treat an eye condition, comprising:
-
loading an implantation device with one or more bodies of drug delivery polymer impregnated with the therapeutic agent and adapted to elute the therapeutic agent over time; forming an incision in the cornea of the eye; passing the implantation device through the incision into the eye along a pathway through the anterior chamber and into at least a portion of the supraciliary space; implanting the one or more bodies with the implantation device into a location in the eye; and eluting the therapeutic agent from the one or more bodies. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24)
-
-
25. A method of delivering to the eye a therapeutic agent to treat an eye condition, comprising:
-
loading an implantation device with a filamentous body comprising a shape memory material and a drug delivery polymer impregnated with the therapeutic agent adapted to elute the therapeutic agent over time; forming an incision in the cornea of the eye; passing the implantation device through the incision into the eye along a pathway through the anterior chamber and into at least a portion of the supraciliary space; implanting the filamentous body with the implantation device into a location in the eye such that the filamentous body changes from a first shape to a second shape upon release from the implantation device into the eye, wherein the first shape is relatively straight and the second shape is coiled; and eluting the therapeutic agent from the filamentous body into the eye. - View Dependent Claims (26, 27)
-
-
28. A device to deliver to a location in the eye a therapeutic agent to treat an eye condition, the device comprising:
a filamentous body comprising a shape memory material and a drug delivery polymer impregnated with the therapeutic agent adapted to elute the therapeutic agent over time, wherein the filamentous body changes from a first shape that is relatively straight to a second shape that is coiled upon release from an implantation device into the eye. - View Dependent Claims (29, 30, 31)
-
32. A device for delivering to an eye a therapeutic agent to treat an eye condition, comprising:
an elongate, filamentous body having a proximal end and a distal end and comprising a polymer matrix impregnated with the therapeutic agent that is adapted to elute the therapeutic agent into the eye over time, wherein the proximal end is adapted for at least partial placement in a first location of the eye, and wherein the distal end is adapted to extend to a second location within the eye. - View Dependent Claims (33, 34, 35, 36)
Specification